DTG50mg+3TC300mg+TDF300mg tabs/PAC-30

General description:
Dolutegravir 50mg + Lamivudine 300mg + Tenofovir disoproxil fumarate 300mg tablets in a bottle pack of 30 with or without outer carton. This product also comes in other pack sizes (90s, 180s).

Technical specifications:
Each tablet contains Dolutegravir 50mg + Lamivudine 300mg + Tenofovir disoproxil fumarate 300mg which is equivalent to 245mg of Tenofovir Disoproxil as fixed dose combination (FDC).

Therapeutic class:
Dolutegravir is an Integrase Inhibitor
Lamivudine is a Nucleoside Reverse Transcriptase Inhibitors (NRTI).
Tenofovir is a Nucleotide Reverse Transcriptase Inhibitor (NtRTI)

Indications:
Management of HIV infection in children and adults. Administration by mouth (oral), PO.

Dosage, Instructions for use:
Please refer to the guideline WHO Model Formulary 2008:
http://apps.who.int/iris/bitstream/handle/10665/44053/9789241547659_eng. pdf?sequence=1
https://www.who.int/publications/i/item/9789241547659
For more details, please see WHO treatment guidelines https://www.who.int/publications/i/item/9789240031593 and WHO Essential Medicines Library https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2021.02 or your regional/national guidelines.

Shelf life:
24 months

Storage and transportation:
Do not store above 30ºC, protect from light.
Store in tightly closed original container.
Keep out of reach and sight of children.

Component of a Kit:
This item is a component of S9901023 - IEHK2017, PEP kit (S1400652 - DTG50mg+3TC300mg+TDF300mg tabs/PAC-30 gb)

Alternative products:
The product may also be available in other formulations, pack sizes, or in combinations with other ARVs